Date  
5/11/23
BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress
5/8/23
BioAtla to Participate in the JMP Securities Life Sciences Conference
5/4/23
BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023
3/23/23
BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
3/16/23
BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights
2/27/23
BioAtla Announces Change in Executive Leadership
2/23/23
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
1/10/23
BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones